Autolus Therapeutics plc Files 2023 10-K

TL;DR

Autolus Therapeutics filed its 2023 10-K, detailing financials and operations for the year ending Dec 31, 2023.

AI Summary

Autolus Therapeutics plc filed its 2023 10-K on March 21, 2024, reporting on its operations for the fiscal year ending December 31, 2023. The company, based in London, is involved in the biological products sector, specifically focusing on cell therapies. The filing details its financial performance and business activities for the period.

Why It Matters

This filing provides investors and stakeholders with a comprehensive overview of Autolus Therapeutics' financial health and strategic direction for the past fiscal year, crucial for understanding its current market position and future prospects.

Risk Assessment

Risk Level: medium — As a biotechnology company, Autolus Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market adoption, which are typical for the sector.

Key Numbers

• 2023-12-31 — Fiscal Year End (The period covered by the 10-K filing.)
• 2024-03-21 — Filing Date (The date Autolus Therapeutics plc submitted its 10-K to the SEC.)

Key Players & Entities

• Autolus Therapeutics plc (company) — Filer of the 10-K report
• 2023-12-31 (date) — Fiscal year end date
• 2024-03-21 (date) — Filing date of the 10-K
• London (location) — Company's business address

FAQ

From the Filing

0001730463-24-000048.txt : 20240321 0001730463-24-000048.hdr.sgml : 20240321 20240321165559 ACCESSION NUMBER: 0001730463-24-000048 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 234 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240321 DATE AS OF CHANGE: 20240321 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Autolus Therapeutics plc CENTRAL INDEX KEY: 0001730463 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38547 FILM NUMBER: 24772090 BUSINESS ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP BUSINESS PHONE: 44 20 3829 6230 MAIL ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP FORMER COMPANY: FORMER CONFORMED NAME: Autolus Therapeutics Ltd DATE OF NAME CHANGE: 20180205 10-K 1 autl-20231231.htm 10-K autl-20231231 0001730463 false 2023 FY True 1 1.5 eleven months fifteen months .5 9 years, 11 months 0001730463 2023-01-01 2023-12-31 0001730463 dei:AdrMember 2023-01-01 2023-12-31 0001730463 autl:OrdinarySharesMember 2023-01-01 2023-12-31 0001730463 2023-06-30 iso4217:USD 0001730463 2024-03-20 xbrli:shares 0001730463 2023-10-01 2023-12-31 0001730463 2023-12-31 0001730463 2022-12-31 0001730463 autl:OrdinarySharesMember 2023-12-31 iso4217:USD xbrli:shares 0001730463 autl:OrdinarySharesMember 2022-12-31 0001730463 autl:DeferredClassASharesMember 2022-12-31 iso4217:GBP xbrli:shares 0001730463 autl:DeferredClassASharesMember 2023-12-31 0001730463 autl:DeferredClassBSharesMember 2023-12-31 0001730463 autl:DeferredClassBSharesMember 2022-12-31 0001730463 autl:DeferredClassCSharesMember 2023-12-31 0001730463 autl:DeferredClassCSharesMember 2022-12-31 0001730463 us-gaap:GrantMember 2023-01-01 2023-12-31 0001730463 us-gaap:GrantMember 2022-01-01 2022-12-31 0001730463 us-gaap:GrantMember 2021-01-01 2021-12-31 0001730463 us-gaap:LicenseMember 2023-01-01 2023-12-31 0001730463 us-gaap:LicenseMember 2022-01-01 2022-12-31 0001730463 us-gaap:LicenseMember 2021-01-01 2021-12-31 0001730463 2022-01-01 2022-12-31 0001730463 2021-01-01 2021-12-31 0001730463 us-gaap:CommonStockMember autl:OrdinarySharesMember 2020-12-31 0001730463 us-gaap:CommonStockMember autl:DeferredClassASharesMember 2020-12-31 0001730463 autl:DeferredClassBSharesMember us-gaap:CommonStockMember 2020-12-31 0001730463 us-gaap:CommonStockMember autl:DeferredClassCSharesMember 2020-12-31 0001730463 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001730463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001730463 us-gaap:RetainedEarningsMember 2020-12-31 0001730463 2020-12-31 0001730463 us-gaap:CommonStockMember autl:OrdinarySharesMember 2021-01-01 2021-12-31 0001730463 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001730463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001730463 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001730463 us-gaap:CommonStockMember autl:OrdinarySharesMember 2021-12-31 0001730463 us-gaap:CommonStockMember autl:DeferredClassASharesMember 2021-12-31 0001730463 autl:DeferredClassBSharesMember us-gaap:CommonStockMember 2021-12-31 0001730463 us-gaap:CommonStockMember autl:DeferredClassCSharesMember 2021-12-31 0001730463 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001730463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001730463 us-gaap:RetainedEarningsMember 2021-12-31 0001730463 2021-12-31 0001730463 us-gaap:CommonStockMember autl:OrdinarySharesMember 2022-01-01 2022-12-31 0001730463 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001730463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001730463 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001730463 us-gaap:CommonStockMember autl:OrdinarySharesMember 2022-12-